Patents by Inventor Jingyang Zhu

Jingyang Zhu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200206621
    Abstract: A method and apparatus for controlling game applications are provided. In the method, when an operating system receives a game starting command, the operating system determines a manner to start a corresponding game application according to whether the game application has resided in a memory, and when a cold boot manner is used, the operating system triggers the game application to report an amount of memory required currently by the game application, and determines whether a requirement of running the game application is met according to the amount of memory required and an amount of memory currently used, or the operating system ensures to meet the requirement of running the game application through background application freezing and clearing.
    Type: Application
    Filed: December 26, 2019
    Publication date: July 2, 2020
    Inventors: Huaiwei JU, Hua LIU, Kun ZHOU, Yong HUANG, Yuan LI, Chao ZHU, Chengming XIA, Wenfang ZHAO, Ying WANG, Jingyang JIA, Pan WANG
  • Publication number: 20200157108
    Abstract: The present invention relates to PDE9 inhibitors, their synthesis, and their use for treatment of benign prostate hyperplasia, beta thalassemia, and sickle cell disease.
    Type: Application
    Filed: May 25, 2018
    Publication date: May 21, 2020
    Inventors: Niels SVENSTRUP, Jun ZHANG, Jikui SUN, Yuyin CHEN, Jianshe KONG, Rujian MA, Junhua ZHANG, Liang QIN, Huanming XIAO, Jinxu SUN, Xiao MENG, Fenglai SUN, Jingyang ZHU
  • Patent number: 8558023
    Abstract: A process for preparing an enantiomerically enriched cycloalkene-substituted alanine compound having the structure: by asymmetrically hydrogenating a dehydro amino acid compound having the structure: in a suitable reaction media in the presence of a catalyst having a transition metal moiety complexed to a chiral phosphine ligand to prepare enantiomerically enriched cycloalkene substituted alanine compounds having the structure of Formula (IA) or (IB), which are key intermediates for the ACE inhibitors ramipril and perindolpril:
    Type: Grant
    Filed: April 20, 2011
    Date of Patent: October 15, 2013
    Assignee: Chiral Quest, Inc.
    Inventors: Zijun Liu, Sanhui Lin, Wenge Li, Jingyang Zhu, Xinjun Liu, Xiaojuan Zhang, Hui Lu, Fei Xiong, Zhongwei Tian
  • Patent number: 8278486
    Abstract: A process for producing an enantiomerically enriched compound of Formula I: where the R-configuration, or S-configuration at the stereogenic center is marked with an *; by hydrogenating an enamide of formula III: in an organic solvent in the presence of a catalyst comprising a transition metal selected from rhodium or iridium, complexed to a chiral diphosphine ligand; Ar is optionally substituted phenyl; Z is OR1, SR1 or NR1R2; and P is R3, OR3 or NR3R4; R1 and R2 are selected from H, C1-8 alkyl, C5-12 cycloalkyl, aryl and aryl-C1-2-alkyl; or R1 and R2 together with the nitrogen atom form a C4-7-membered heterocyclic ring optionally fused with a 5- to 6-membered carbocyclic or heterocyclic ring; and R3 and R4 are selected from H, C1-8 alkyl, aryl, C5-12 cycloalkyl and aryl-C1-2-alkyl; or R3 and R4 together with the nitrogen atom form a C4-7-membered heterocyclic ring.
    Type: Grant
    Filed: December 30, 2009
    Date of Patent: October 2, 2012
    Assignee: Chiral Quest, Inc.
    Inventors: Shulin Wu, Bo Yu, Yejing Wang, Alain Delice, Jingyang Zhu
  • Publication number: 20110257408
    Abstract: A process for preparing an enantiomerically enriched cycloalkene-substituted alanine compound having the structure: by asymmetrically hydrogenating a dehydro amino acid compound having the structure: in a suitable reaction media in the presence of a catalyst having a transition metal moiety complexed to a chiral phosphine ligand to prepare enantiomerically enriched cycloalkene substituted alanine compounds having the structure of Formula (IA) or (IB), which are key intermediates for the ACE inhibitors ramipril and perindolpril:
    Type: Application
    Filed: April 20, 2011
    Publication date: October 20, 2011
    Applicant: Chiral Quest, Inc.
    Inventors: Zijun Liu, Sanhui Lin, Wenge Li, Jingyang Zhu, Xinjun Liu, Xiaojuan Zhang, Hui Lu, Fei Xiong, Zhongwei Tian
  • Publication number: 20100280245
    Abstract: A process for producing an enantiomerically enriched, pure or enriched and essentially pure compound of Formula I: wherein the R-, or S-configuration at the stereogenic center is marked with an *; which process hydrogenates an enamide compound of formula III: in an organic solvent in the presence of a transition metal precursor complexed to a chiral phosphine ligand catalyst; wherein Ar is phenyl which is unsubstituted or substituted; Z is OR1, SR1 and NR1R2; and P is R3, OR3, and NR3R4; R1 and R2 are selected from H, C1-8 alkyl, C5-12 cycloalkyl, aryl and aryl-C1-2-alkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a C4-7-member heterocyclic ring system optionally fused with a 5- to 6-member carbocyclic or heterocyclic ring system; and R3 and R4 are selected from H, C1-8 alkyl, aryl, C5-12 cycloalkyl and aryl-C1-2-alkyl; or R3 and R4 together with the nitrogen atom to which they are attached form a C4-7-member heterocyclic ring system.
    Type: Application
    Filed: December 30, 2009
    Publication date: November 4, 2010
    Inventors: Shulin Wu, Bo Yu, Yejing Wang, Alain Delice, Jingyang Zhu
  • Publication number: 20100217013
    Abstract: An enantioselective process for preparing zolmitriptan, (S)-4-{[3-[2-(dimethylamine)ethyl]-1H-indol-5-yl]methyl}-2-oxazolidinone), by asymmetric hydrogenation of (Z)-2-(acetylamino)-3-{[3-N,N-(dimethylamine)ethyl)-1H-indol-5-yl]-2-propenoic acid methyl ester in the presence of hydrogen and an enantioselective chiral phosphine transition metal catalyst.
    Type: Application
    Filed: December 15, 2009
    Publication date: August 26, 2010
    Inventors: Wenge Li, Yongxiang Chi, Jingyang Zhu
  • Publication number: 20100168385
    Abstract: A process for preparing an enantiomerically enriched amino alcohol or derivatives thereof having the structure: wherein C* is a chiral carbon atom and R1 and R2 are independently selected from hydrogen, alkyl, alkoxy, aryl and a peptide chain, wherein said process includes the steps of: (a) providing an amino acid having the structure of Formula I: (b) protecting the amino group of the Formula I amino acid with a carbobenzoxy(Cbz) N-protecting group by reacting the amino acid with benzyl chloroformate in the presence of a base; (c) forming a carboxylic acid alkyl ester of the Cbz N-protected Formula I amino acid by reacting the amino acid with a C1-12 alcohol; and (d) reducing the Cbz N-protected amino acid ester with a borohydride reducing agent in an organic solvent or mixture of organic solvents to form a Cbz N-protected amino-alcohol
    Type: Application
    Filed: December 21, 2009
    Publication date: July 1, 2010
    Inventors: Yuan WEI, Zhongwei TIAN, Jingyang ZHU
  • Patent number: 7388098
    Abstract: Provided is a dynamic resolution method of enriching a desired isomer of an alpha-substituted carboxylic acid relative to an undesired isomer, the method comprising: (a) in a solvent, contacting the alpha-substituted carboxylic acid, wherein the alpha substitution is with a leaving group and wherein the alpha carbon is chiral, with a homochiral amine to form a salt that is partially insoluble under selected reaction conditions, wherein the homochiral amine is selected so that the solubility of the amine salt of the undesired alpha-substituted carboxylic acid is greater than that of the amine salt of the desired alpha-substituted carboxylic acid under the selected reaction conditions; (b) reacting under the selected reaction conditions the salt with a nucleophile, wherein the reacting is effective in producing a net increase in the less soluble amine salt of the alpha-substituted carboxylic acid, and wherein the selected conditions are selected to (i) promote nucleophilic substitution of the nucleophile and th
    Type: Grant
    Filed: September 24, 2001
    Date of Patent: June 17, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: John J. Venit, Gary D. Madding, Victor W. Rosso, Francis J. Okuniewicz, Robert P. Discordia, Susanne Kiau, Atul S. Kotnis, Michael E. Randazzo, D. David Hennings, Jingyang Zhu, Jason G. Chen
  • Patent number: 7365208
    Abstract: A method for preparing irbesartan and intermediates thereof.
    Type: Grant
    Filed: March 20, 2007
    Date of Patent: April 29, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Edgar I. Miranda, Cornelis Vlaar, Jingyang Zhu
  • Publication number: 20070167634
    Abstract: A method for preparing irbesartan and intermediates thereof.
    Type: Application
    Filed: March 20, 2007
    Publication date: July 19, 2007
    Inventors: Edgar Miranda, Cornelis Vlaar, Jingyang Zhu
  • Patent number: 7211676
    Abstract: A method for preparing irbesartan and intermediates thereof.
    Type: Grant
    Filed: August 22, 2005
    Date of Patent: May 1, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Edgar I. Miranda, Cornelis Vlaar, Jingyang Zhu
  • Patent number: 7141694
    Abstract: Provided is a method of resolving a racemic mixture of a compound of formula I to obtain a desired enantiomer: wherein Ar is C6 or C10 aromatic group that can be substituted with H, C1 to C6 alkyl, trifluoromethyl or halo, R5 is halo or —S—R1, wherein R1 is H or acetyl, and R2 is H or C1 to C6 alkyl, the method comprising: reacting a compound of formula I wherein the compound is an ester whereby R2 is C1 to C6 alkyl with a lipase derived from Mucor meihei to stereoselectively hydrolyze the ester bond to produce an acid; and isolating the acid, wherein the reaction is conducted in a solvent comprising 80% to 98% v/v % organic phase and a residue of water phase (which can be buffered).
    Type: Grant
    Filed: July 23, 2003
    Date of Patent: November 28, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jingyang Zhu, Shannon X. Zhao
  • Patent number: 7026143
    Abstract: Provided is a method of resolving a racemic mixture of a compound of formula I to obtain a desired enantiomer: wherein Ar is C6 or C10 aromatic group that can be substituted with H, C1 to C6 alkyl, trifluoromethyl or halo, R5 is halo or —S—R1, wherein R1 is H or acetyl, and R2 is H or C1 to C6 alkyl, the method comprising: reacting a compound of formula I wherein the compound is an ester whereby R2 is C1 to C6 alkyl with a lipase derived from Mucor meihei to stereoselectively hydrolyze the ester bond to produce an acid; and isolating the acid, wherein the reaction is conducted in a solvent comprising 80% to 98% v/v % organic phase and a residue of water phase (which can be buffered).
    Type: Grant
    Filed: July 23, 2003
    Date of Patent: April 11, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jingyang Zhu, Li You, Brenda J. White, Shannon X. Zha, Paul M. Skonezny
  • Patent number: 7012158
    Abstract: Provided are processes and synthetic intermediates useful for the preparation of ?-difluoromethylornithine (DFMO) having the formula
    Type: Grant
    Filed: February 26, 2004
    Date of Patent: March 14, 2006
    Assignee: Skinmedica, Inc.
    Inventors: Jingyang Zhu, Scott T. Chadwick, Benjamin A. Price, Shannon X. Zhao, Carrie A. Costello, Purushotham Vemishetti
  • Publication number: 20060041147
    Abstract: A method for preparing irbesartan and intermediates thereof.
    Type: Application
    Filed: August 22, 2005
    Publication date: February 23, 2006
    Inventors: Edgar Miranda, Cornelis Vlaar, Jingyang Zhu
  • Publication number: 20060035954
    Abstract: A process is provided for preparing the intermediate A in accordance with the following reaction sequence The intermediate A is used in preparing DPP IV inhibitors which are useful in treating diabetes.
    Type: Application
    Filed: August 8, 2005
    Publication date: February 16, 2006
    Inventors: Padam Sharma, Gabriel Galvin, Susan Boettger, Saibaba Racha, Jingyang Zhu, Jack Melton, Boguslaw Mudryk
  • Publication number: 20040171876
    Abstract: Provided are processes and synthetic intermediates useful for the preparation of &agr;-difluoromethylornithine (DFMO) having the formula 1
    Type: Application
    Filed: February 26, 2004
    Publication date: September 2, 2004
    Applicants: Bristol-Myers Squibb Company, Bristol-Myers Squibb Company to Women First Healthcare, Inc.
    Inventors: Jingyang Zhu, Scott T. Chadwick, Benjamin A. Price, Shannon X. Zhao, Carrie A. Costello, Purushotham Vemishetti
  • Patent number: 6730809
    Abstract: Provided are processes and synthetic intermediates useful for the preparation of &agr;-difluoromethylornithine (DFMO) having the formula
    Type: Grant
    Filed: August 19, 2002
    Date of Patent: May 4, 2004
    Assignee: Women First Healthcare, Inc.
    Inventors: Jingyang Zhu, Scott T. Chadwick, Benjamin A. Price, Shannon X. Zhao, Carrie A. Costello, Purushotham Vemishetti
  • Publication number: 20040077061
    Abstract: Provided is a method of resolving a racemic mixture of a compound of formula I to obtain a desired enantiomer: 1
    Type: Application
    Filed: July 23, 2003
    Publication date: April 22, 2004
    Inventors: Jingyang Zhu, Shannon X. Zhao